PDF(Pubmed)
Abstract：
UNASSIGNED: Cabozantinib use in everyday clinical practice for advanced or metastatic renal cell carcinoma (RCC) is relatively recent, and real-world data on treatment persistence, adherence and sequencing are still limited.
UNASSIGNED: We conducted an analysis based on an integrated administrative database, covering around 6.9 million health-assisted Italian individuals, to explore the use of cabozantinib for RCC. Patients with at least one prescription for cabozantinib during 2017-2020 were searched. These were characterized during all available period (i.e. from 2010 onwards) before the index date and were observed after inclusion.
UNASSIGNED: A total of 113 patients treated with cabozantinib in second or subsequent line were included, and their demographic, clinical and treatment characteristics were described. About half of these RCC patients were aged >65 years (47.8%). Sixty patients (53.1%) were highly adherent to cabozantinib therapy, and the median cabozantinib treatment duration of use was 8.7 months (95% confidence interval: 5.8-11.1). During the first year of follow-up, the average total cost per patient was €32,508.
UNASSIGNED: We described second or subsequent line cabozantinib treatment for RCC in a real-world setting and the economic burden of disease in Italy, taking advantage of large, integrated administrative databases.
UNASSIGNED: We conducted an analysis based on an integrated administrative database, covering around 6.9 million health-assisted Italian individuals, to explore the use of cabozantinib for RCC. Patients with at least one prescription for cabozantinib during 2017-2020 were searched. These were characterized during all available period (i.e. from 2010 onwards) before the index date and were observed after inclusion.
UNASSIGNED: A total of 113 patients treated with cabozantinib in second or subsequent line were included, and their demographic, clinical and treatment characteristics were described. About half of these RCC patients were aged >65 years (47.8%). Sixty patients (53.1%) were highly adherent to cabozantinib therapy, and the median cabozantinib treatment duration of use was 8.7 months (95% confidence interval: 5.8-11.1). During the first year of follow-up, the average total cost per patient was €32,508.
UNASSIGNED: We described second or subsequent line cabozantinib treatment for RCC in a real-world setting and the economic burden of disease in Italy, taking advantage of large, integrated administrative databases.
摘要：
■卡博替尼用于晚期或转移性肾细胞癌（RCC）的日常临床实践相对较新，和关于治疗持久性的真实世界数据，依从性和测序仍然有限。
■我们基于综合管理数据库进行了分析，涵盖约690万健康援助的意大利人，探讨卡博替尼用于RCC。搜索了2017-2020年期间至少有一种卡博替尼处方的患者。在索引日期之前的所有可用期间（即从2010年开始）对这些进行了表征，并在纳入后进行了观察。
■共113名患者在第二或后续行接受卡博替尼治疗，和他们的人口统计，阐述了临床特点和治疗特点。这些RCC患者中约有一半年龄>65岁（47.8％）。60例患者（53.1%）高度坚持卡博替尼治疗，卡博替尼治疗持续时间中位数为8.7个月(95%置信区间:5.8-11.1).在随访的第一年，每名患者的平均总费用为32,508欧元.
■我们描述了在现实世界中治疗RCC的第二行或后续行卡博替尼治疗以及意大利疾病的经济负担，利用大的优势，综合管理数据库。
■我们基于综合管理数据库进行了分析，涵盖约690万健康援助的意大利人，探讨卡博替尼用于RCC。搜索了2017-2020年期间至少有一种卡博替尼处方的患者。在索引日期之前的所有可用期间（即从2010年开始）对这些进行了表征，并在纳入后进行了观察。
■共113名患者在第二或后续行接受卡博替尼治疗，和他们的人口统计，阐述了临床特点和治疗特点。这些RCC患者中约有一半年龄>65岁（47.8％）。60例患者（53.1%）高度坚持卡博替尼治疗，卡博替尼治疗持续时间中位数为8.7个月(95%置信区间:5.8-11.1).在随访的第一年，每名患者的平均总费用为32,508欧元.
■我们描述了在现实世界中治疗RCC的第二行或后续行卡博替尼治疗以及意大利疾病的经济负担，利用大的优势，综合管理数据库。
